Cargando…
A Pharmacogenetic Investigation of Intravenous Furosemide in Decompensated Heart Failure: A Meta-Analysis of 3 Clinical Trials
We conducted a meta-analysis of pharmacogenomic substudies of three randomized trials conducted in patients with decompensated heart failure (HF) which were led by National Heart Lung and Blood Institute (NHLBI)-funded HF Network to test the hypothesis that candidate genes modulate net fluid loss an...
Autores principales: | de Denus, Simon, Rouleau, Jean L, Mann, Douglas L., Huggins, Gordon S., Cappola, Thomas P., Shah, Svati H., Keleti, Julianna, Zada, Yassamin Feroz, Provost, Sylvie, Bardhadi, Amina, Phillips, Michael S., Normand, Valérie, Mongrain, Ian, Dubé, Marie-Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009007/ https://www.ncbi.nlm.nih.gov/pubmed/26927285 http://dx.doi.org/10.1038/tpj.2016.4 |
Ejemplares similares
-
CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction
por: de Denus, Simon, et al.
Publicado: (2017) -
A genetic association study of heart failure: more evidence for the role of BAG3 in idiopathic dilated cardiomyopathy
por: de Denus, Simon, et al.
Publicado: (2020) -
Impact of regular physical activity on weekly warfarin dose requirement
por: Rouleau-Mailloux, Étienne, et al.
Publicado: (2015) -
Nuclear receptor gene polymorphisms and warfarin dose requirements in the Quebec Warfarin Cohort
por: Shahabi, Payman, et al.
Publicado: (2018) -
Ambulatory intravenous furosemide for decompensated heart failure: safe, feasible, and effective
por: Ahmed, Fozia Z., et al.
Publicado: (2021)